Abstract submission
is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013.
The congress includes symposia, keynote lectures and peer-reviewed oral and
poster communications.
Symposium on the dopamine D3
receptor as a potential target for psychiatric diseases
Peculiar cerebral distribution of the dopamine D3 receptor predisposes
it to be an attractive drug target in
psychiatric diseases. Preclinical results highlighting the function of the D3
receptor in cognition, mood and motor function are promising, yet only few
drugs with prominent D3 receptor action have reached the clinic so far. This is
in sharp contrast to the case of the dopamine D2 receptor, its closest
relative, whose ligands are widely used in various CNS disorders. The symposium
provides an overview - along with a comparison with the D2 receptor – on the characteristics
of the D3 receptor, compounds acting at this receptor and their pharmacology
and therapeutic potential.
2013 EACPT Congress
Over 900 participants are expected to attend including
health professionals, scientists, policy makers, biotechnology and
pharmaceutical professionals, and others with an interest
in basic and clinical pharmacology, pharmacotherapy,
drug discovery and development, regulatory affairs and related
areas.
EACPT Geneva 2013 Congress website
www.eacpt2013.org
No comments:
Post a Comment